Journal of Substance Abuse Treatment
Volume 31, Issue 4 , Pages 319-328 , December 2006

Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia

  • Evgeny M. Krupitsky, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Edwin E. Zvartau, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Dimitry V. Masalov, M.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Marina V. Tsoy, M.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Andrey M. Burakov, M.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Valentina Y. Egorova, M.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Tatyana Y. Didenko, M.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Tatyana N. Romanova, M.S.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Eva B. Ivanova, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Anton Y. Bespalov, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Elena V. Verbitskaya, Ph.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Nikolai G. Neznanov, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Alexandr Y. Grinenko, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific-Research Center of Addictions and Psychopharmacology (affiliated with St. Petersburg State Pavlov Medical University and Bekhterev Research Psychoneurological Institute), St. Petersburg, Russia
    • ,
  • Charles P. O'Brien, M.D., Ph.D.

      Affiliations

    • Department of Psychiatry and Veterans Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, USA
    • ,
  • George E. Woody, M.D.

      Affiliations

    • Department of Psychiatry and Veterans Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, USA
    • Corresponding Author InformationCorresponding author. Treatment Research Institute, 600 Public Ledger Building, 150 South Independence Mall (W) Philadelphia, PA 19106, USA.

Received 1 March 2006 ,Revised 12 May 2006 ,Accepted 12 May 2006.

References 

  1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561–571
  2. Carroll KM, Ball SA, Nick C, O'Connor PG, Egan DA, Frankforter TL, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence—Efficacy of contingency management and significant other involvement. Archives of General Psychiatry. 2001;58:755–761
  3. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment. 1997;14:529–534
  4. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition (DSM-IV). In:  Frances A,  Pincus H,  First MB editor. Substance related disorders. 1994;p. 175–272
  5. Fals-Stewart W, O'Farrell T. Behavioral family counseling and naltrexone for male opioid-dependent patients. Journal of Consulting and Clinical Psychology. 2003;71:432–442
  6. Judson BA, Carney TM, Goldstein A. Naltrexone treatment of heroin addiction: Efficacy and safety in a double blind dosage comparison. Drug Alcohol Dependence. 1981;7:325–346
  7. Kleber H, Kosten T, Gaspari J. Nontolerance to opioid antagonism of naltrexone. Biological Psychiatry. 1985;20:66–72
  8. Krupitsky E, Zvartau E, Karandashova G, Horton NJ, Schoolwerth KR, Bryant K, et al. The onset of HIV infection in the Leningrad Region of Russia: A focus on drug and alcohol dependence. HIV Medicine. 2004;5:30–33
  9. Krupitsky EM, Burakov AM, Didenko TY, Romanova TN, Grinenko NI, Slavina AY, et al. Effects of citalopram treatment of protracted withdrawal (syndrome of anhedonia) in patients with heroin addiction. Addictive Disorders & Their Treatment. 2002;1:29–33
  10. Krupitsky EM, Burakov AM, Romanova TN, Dunaevsky IV, Strassman R, Grinenko AY. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. Journal of Substance Abuse Treatment. 2002;23:273–283
  11. Krupitsky EM, Burakov AM, Romanova TN, Vostrikov VV, Grinenko AY. The syndrome of anhedonia in recently detoxified heroin addicts: Assessment and treatment. In:  Harris LS editors. Abstracts of the international meeting Building International Research on Drug Abuse: Global Focus on Youth. Scottsdale, AZ: National Institute on Drug Abuse; 1998;p. 15
  12. Krupitsky EM, Zvartau EE, Lioznov DA, Tsoy MV, Egorova VY, Belyaeva TV, et al. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia. European Addiction Research. 2006;12:12–19
  13. Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment. 2004;26:285–294
  14. McLellan AT, Luborsky L, Cacciola J, Griffith J. New data from the Addiction Severity Index: Reliability and validity in three centers. Journal of Nervous and Mental Disease. 1985;173:412–423
  15. Mercer D, Woody GE. The Penn-VA addiction counseling manual. 1998;Available at http://www.nida.nih.gov(Accessed September 30, 2005)
  16. Navaline HA, Snider EC, Petro C, Tobin D, Metzger D, Alterman A, et al. Preparations for AIDS vaccine trials. An automated version for the Risk Assessment Battery (RAB): Enhancing the assessment of risk behaviors. AIDS Research and Human Retroviruses. 1994;10:281–283
  17. O'Brien CP, Childress AR, McLellan AT, Ternes JM, Ehrman R. Use of naltrexone to extinguish opioid conditioned responses. Journal of Clinical Psychiatry. 1984;45:53–56(No. 8, Section 2)
  18. O'Brien CP, Greenstein R, Mintz J, Woody GE. Clinical experience with naltrexone. American Journal of Drug and Alcohol Abuse. 1975;2:365–377
  19. O'Malley SS, Jaffe A, Chang G, Schottenfeld RS, Meyer RE, Rounsaville BJ. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry. 1992;49:881–887
  20. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812
  21. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported alcohol consumption. In:  Litten R,  Allen J editor. Measuring alcohol consumption. New York: Humana Press; 1992;p. 41–72
  22. Spielberger CD, Anton WD, Bedell J. In:  Zuckerman M,  Spielberger CD editor. The nature and treatment of test anxiety. Emotion and anxiety: New concepts, methods and applications. Hillsdale, NJ: Erlbaum; 1976;
  23. Tennant FS, Rawson RA, Cohen AI, Mann A. Clinical experience with naltrexone in suburban opioid addicts. Journal of Clinical Psychiatry. 1984;45:42–45
  24. Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. Journal of Clinical Psychiatry. 1984;45:39–41

PII: S0740-5472(06)00145-0

doi: 10.1016/j.jsat.2006.05.005

Journal of Substance Abuse Treatment
Volume 31, Issue 4 , Pages 319-328 , December 2006

Article Tools

* Image Usage & Resolution